3 results
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
The goal of this investigation is to show that Hemospray is effective in achieving initial hemostasis rates equivalent to standard of care treatment and a decreased rate of further bleed when compared to standard of care up to 72 hours after…
Concluding, the aim of current study is to show feasibility of the MaMaLoc technology for surgical localization of clinically occult melanoma lesions, as well as to show feasibility of the MaMaLoc technology for lymph node detection, both in the…